The effect of dutasteride on the detection of prostate cancer: A set of meta-analyses

Journal of the Canadian Urological Association

Volumn 7, Issue 3, 2013, Pages

  Monga, Neerav ^a   Sayani, Amyn ^a   Rubinger, Daniel A ^a   Wilson, Timothy H ^b   Su, Zhen ^a  

^a GLAXOSMITHKLINE   (Canada)

^b GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84875435240     PISSN: 19116470     EISSN: None     Source Type: Journal    
DOI: 10.5489/cuaj.477     Document Type: Article

References (25)

1. Berry SJ, Coffey DS, Walsh PC, et al. The Development of Human Benign Prostatic Hyperplasia With Age. J Urol 1984;132:474-9.
2. Garcia M, Jemal A, Ward EM, et al. Global Cancer Facts & Figures 2007. 2007. Atlanta, GA. Available at http://www.cancer.org/acs/groups/content/@nho/documents/document/globalfactsandfigures-2007rev2p.pdf. Accessed March 7, 2013.
3. Rawson N, Saad F. The Aging Male Population and Medical Care for Benign Prostatic Hyperplasia in Canada. Can Urol Assoc J 2010;4:123-7. http://dx.doi.org/10.5489/cuaj.09092
4. Wei JT, Calhoun E, Jacobsen SJ. Urologic Diseases in America Project: Benign Prostatic Hyperplasia. J Urol 2005;173:1256-61. http://dx.doi.org/10.1097/01.ju.0000155709.37840.fe
5. Roehrborn CG, Boyle P, Nickel JC, et al. Efficacy and Safety of a Dual Inhibitor of 5-Alpha-Reductase Types 1 and 2 (Dutasteride) in Men With Benign Prostatic Hyperplasia. Urology 2002;60:434-441. http:// dx.doi.org/10.1016/S0090-4295(02)01905-2
6. Clark RV, Hermann DJ, Cunningham GR, et al. Marked Suppression of Dihydrotestosterone in Men With Benign Prostatic Hyperplasia by Dutasteride, a Dual 5alpha-Reductase Inhibitor. J Clin Endocrinol Metab 2004;89:2179-84. http://dx.doi.org/10.1210/jc.2003-030330
7. Gormley GJ, Stoner E, Bruskewitz RC, et al. The Effect of Finasteride in Men With Benign Prostatic Hyperplasia. N Engl J Med 1992;327:1185-91. http://dx.doi.org/10.1056/NEJM199210223271701
8. Andriole GL, Roehrborn C, Schulman C, et al. Effect of Dutasteride on the Detection of Prostate Cancer in Men With Benign Prostatic Hyperplasia. Urology 2004;64:537-41. http://dx.doi.org/10.1016/j.urology.2004.04.084
9. Roehrborn CG, Andriole GL, Wilson TH, et al. Effect of Dutasteride on Prostate Biopsy Rates and the Diagnosis of Prostate Cancer in Men With Lower Urinary Tract Symptoms and Enlarged Prostates in the Combination of Avodart and Tamsulosin Trial. Eur Urol 2011;59:244-9. http://dx.doi.org/10.1016/j.eururo.2010.10.040
10. Thompson IM, Goodman PJ, Tangen CM, et al. The Influence of Finasteride on the Development of Prostate Cancer. N Engl J Med 2003;349:215-24. http://dx.doi.org/10.1056/NEJMoa030660
11. Andriole GL, Bostwick DG, Brawley OW, et al. Effect of Dutasteride on the Risk of Prostate Cancer. N Engl J Med 2010;362:1192-202. http://dx.doi.org/10.1056/NEJMoa0908127
12. Theoret MR, Ning YM, Zhang JJ, et al. The Risks and Benefits of 5a-Reductase Inhibitors for Prostate-Cancer Prevention. N Engl J Med 2011;365:97-99. http://dx.doi.org/10.1056/NEJMp1106783
13. Fleshner NE, Lucia MS, Egerdie B, et al. Dutasteride in Localised Prostate Cancer Management: the REDEEM Randomised, Double-Blind, Placebo-Controlled Trial. Lancet 2012;379:1103-1111. http://dx.doi.org/10.1016/S0140-6736(11)61619-X
14. Lau J, Ioannidis JPA, Schmid CH. Quantitative Synthesis in Systematic Reviews. Ann Intern Med 1997;127:820-826.
15. Zintzaras E, Ioannidis JPA. Heterogeneity Testing in Meta-Analysis of Genome Searches. Genet Epidemiol 2005;28:123-37. http://dx.doi.org/10.1002/gepi.20048
16. Borenstein M, Hedges L, Higgins J, et al. Comprehensive Meta-analysis, Version 2, Biostat, Englewood NJ; 2005.
17. Andriole GL, Bostwick D, Brawley OW, et al. The Effect of Dutasteride on the Usefulness of Prostate Specific Antigen for the Diagnosis of High Grade and Clinically Relevant Prostate Cancer in Men With a Previous Negative Biopsy: Results From the REDUCE Study. J Urol 2011;185:126-31. http://dx.doi.org/10.1016/j.juro.2010.09.011
18. Marberger M, Freedland SJ, Andriole GA, et al. Usefulness of prostate-specific antigen (PSA) rise as a marker of prostate cancer in men treated with dutasteride: lesson from the REDUCE study. BJU Int 2012;109:1162-9. http://dx.doi.org/10.1111/j.1464-410X.2011.10373.x
19. Kaplan SA, Lee RK, Chung DE, et al. Prostate biopsy in response to a change in nadir prostate specific antigen of 0.4 ng/mL after treatment with 5α-reductase inhibitors markedly enhances the detection rate of prostate cancer. J Urol 2012;188:757-61. http://dx.doi.org/10.1016/j.juro.2012.04.111
20. Yafi FA, Aprikian AG, Tanguay S, et al. Are Men on 5alpha-Reductase Inhibitors Appropriately Referred to Urology? A Survey of Primary Care Physicians. BJU Int 2011;108:1269-73. http://dx.doi.org/10.1111/j.1464-410X.2010.09984.x
21. Epstein, JI, Allsbrook, Amin MB, et al. The 2005 International Society of Urological Pathology (ISUP), Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol 2005;29:1228-42.
22. Delahunt B, Lamb DS, Srigley JR, et al. Gleason Scoring: a Comparison of Classical and Modified (International Society of Urological Pathology) Criteria Using Nadir PSA As a Clinical End Point. Pathology 2010;42:339-43. http://dx.doi.org/10.3109/00313021003787924
23. Billis A, Guimaraes MS, Freitas LL, et al. The Impact of the 2005 International Society of Urological Pathology Consensus Conference on Standard Gleason Grading of Prostatic Carcinoma in Needle Biopsies. J Urol 2008;180:548-52. http://dx.doi.org/10.1016/j.juro.2008.04.018
24. Helpap B, Egevad L. Modified Gleason Grading. An Updated Review. Histol Histopathol 2009;24:661-6.
25. Klotz L, Chetner M, Chin J, et al. Canadian Consensus Conference: The FDA decision on the use of 5ARIs. Can Urol Assoc J 2012;6:83-8.